Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients
Brain metastases incidence increases per line of therapy for every MBC subtype. The HER2-low biomarker does not impact brain metastases incidence within historical subtypes.
Authors
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Filippo Montemurro (ORCID: https://orcid.org/0000-0003-4231-2291)
- Timothy K. Erick (ORCID: https://orcid.org/0000-0002-6855-2528)
- Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
- José Pablo Leone (ORCID: https://orcid.org/0000-0002-8537-652X)
- Raf Poppe (ORCID: https://orcid.org/0000-0001-9434-2674)
- Peter Lambert (ORCID: https://orcid.org/0000-0001-5313-4158)
- Eleonora Restuccia (ORCID: https://orcid.org/0000-0001-5751-094X)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Thibaut Sanglier (ORCID: https://orcid.org/0000-0003-0740-2048)
Institutions
- Roche (Switzerland) (CH)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1093/jnci/djaf048
- Citations
- 8
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 12.15